 MONROVIA, Calif.--BUSINESS WIRE--Xencor, Inc. NASDAQ:XNCR, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in a pre-recorded fireside chat at the H.C. Wainwright Bioconnect Virtual Conference. The on-demand recording will be available under Events Presentations in the Investors section of the Companys website located at w 